Diabetic Retinopathy Market Research Report Information by Type (Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR)), by Treatment (Pharmacological Therapies, Laser Treatment, and Surgery), by End User (Hospitals & Clinics, Ophthalmology Centers, and Research Institutes), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Research Objective

2.4. Assumptions

2.5. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Technique

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. COVID-19 Impact Analysis

5.2.1. Market Impact Analysis

5.2.2. Regional Impact

5.2.3. Impact on Supply Chain

6. GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE

6.1. Overview

6.2. Non-Proliferative Diabetic Retinopathy (NPDR)

6.3. Proliferative Diabetic Retinopathy (PDR)

7. GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT

7.1. Overview

7.2. Pharmacological Therapies

7.2.1. Anti-VEGF Injections

7.2.2. Corticosteroids

7.3. Laser Treatment

7.4. Surgery

8. GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

8.3. Ophthalmology Centers

8.4. Research Institutes

9. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Diabetic Retinopathy Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Diabetic Retinopathy Market

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

11. COMPANY PROFILES

11.1. Novartis AG

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Bayer AG

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. F. Hoffmann-La Roche Ltd

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Regeneron Pharmaceuticals Inc.

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Carl Zeiss

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Optos

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Genentech, Inc.

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. AbbVie

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Eli Lilly and Company

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Viatris

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL DIABETIC RETINOPATHY MARKET, SYNOPSIS, 2019–2032

TABLE 2 GLOBAL DIABETIC RETINOPATHY MARKET, ESTIMATES & FORECAST, 2019–2032 (USD BILLION)

TABLE 3 GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 6 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 7 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 9 US: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 10 US: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 11 US: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 12 CANADA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 13 CANADA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 14 CANADA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 15 EUROPE: DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 1 EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 2 EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 3 EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 4 GERMANY: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 5 GERMANY: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 6 GERMANY: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 7 FRANCE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 8 FRANCE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 9 FRANCE: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 10 ITALY: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 11 ITALY: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 12 ITALY: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 13 SPAIN: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 14 SPAIN: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 15 SPAIN: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 16 UK: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 17 UK: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 18 UK: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 19 REST OF EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 20 REST OF EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 21 REST OF EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 25 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 26 JAPAN: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 27 JAPAN: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 28 JAPAN: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 29 CHINA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 30 CHINA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 31 CHINA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 32 INDIA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 33 INDIA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 34 INDIA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 35 AUSTRALIA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 36 AUSTRALIA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 37 AUSTRALIA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 38 SOUTH KOREA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 39 SOUTH KOREA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 40 SOUTH KOREA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 43 REST OF ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 46 REST OF THE WORLD: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 47 REST OF THE WORLD: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 48 MIDDLE EAST: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 49 MIDDLE EAST: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 50 MIDDLE EAST: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 51 AFRICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 52 AFRICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 53 AFRICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 54 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 55 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2019–2032 (USD BILLION)

TABLE 56 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2019–2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DIABETIC RETINOPATHY MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DIABETIC RETINOPATHY MARKET

FIGURE 4 GLOBAL DIABETIC RETINOPATHY MARKET, SHARE (%), BY TYPE, 2023

FIGURE 5 GLOBAL DIABETIC RETINOPATHY MARKET, SHARE (%), BY TREATMENT, 2023

FIGURE 6 GLOBAL DIABETIC RETINOPATHY MARKET, SHARE (%), BY END USER, 2023

FIGURE 7 GLOBAL DIABETIC RETINOPATHY MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, SHARE (%), BY COUNTRY, 2023

FIGURE 9 EUROPE: DIABETIC RETINOPATHY MARKET, SHARE (%), BY COUNTRY, 2023

FIGURE 10 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, SHARE (%), BY COUNTRY, 2023

FIGURE 11 REST OF THE WORLD: DIABETIC RETINOPATHY MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 GLOBAL DIABETIC RETINOPATHY MARKET: COMPANY SHARE ANALYSIS (%), 2023

FIGURE 13 NOVARTIS AG: SWOT ANALYSIS

FIGURE 14 BAYER AG: SWOT ANALYSIS

FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 16 REGENERON PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 17 CARL ZEISS: SWOT ANALYSIS